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work required more than 20 meetings to obtain a consensus 
on each item from the working group. Then four forums were 
held to permit examination of the Guideline details in Japan, 
both by an external assessment committee and by the working 
group participants (version 2). As we knew that the diagnosis 
and management of acute biliary infection may differ from 
country to country, we appointed a publication committee and 
held 12 meetings to prepare draft Guidelines in English (ver-
sion 3). We then had several discussions on these draft guide-
lines with leading experts in the ﬁ  eld throughout the world, 
via e-mail, leading to version 4. Finally, an International Con-
sensus Meeting took place in Tokyo, on 1–2 April, 2006, to 
obtain international agreement on diagnostic criteria, severity 
assessment, and management.
Key words  Cholangitis · Cholecystitis · Charcot’s triad · 
Reynold’s pentad · Biliary drainage
Introduction
No guidelines focusing on the management of biliary 
infection (cholangitis and cholecystitis) have previously 
been published, and no worldwide criteria exist for 
diagnostic and severity assessment. “Charcot’s triad”1 is 
still used for the diagnosis of acute cholangitis. How-
Abstract
There are no evidence-based-criteria for the diagnosis, sever-
ity assessment, of treatment of acute cholecysitis or acute 
cholangitis. For example, the full complement of symptoms 
and signs described as Charcot’s triad and as Reynolds’ pen-
tad are infrequent and as such do not really assist the clinician 
with planning management strategies. In view of these factors, 
we launched a project to prepare evidence-based guidelines 
for the management of acute cholangitis and cholecystitis that 
will be useful in the clinical setting. This research has been 
funded by the Japanese Ministry of Health, Labour, and Wel-
fare, in cooperation with the Japanese Society for Abdominal 
Emergency Medicine, the Japan Biliary Association, and the 
Japanese Society of Hepato-Biliary-Pancreatic Surgery. A 
working group, consisting of 46 experts in gastroenterology, 
surgery, internal medicine, emergency medicine, intensive 
care, and clinical epidemiology, analyzed and examined the 
literature on patients with cholangitis and cholecystitis in or-
der to produce evidence-based guidelines. During the investi-
gations we found that there was a lack of high-level evidence, 
for treatments, and the working group formulated the guide-
lines by obtaining consensus, based on evidence categorized 
by level, according to the Oxford Centre for Evidence-Based 
Medicine Levels of Evidence of May 2001 (version 1). This 
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ever, these criteria were ﬁ  rst proposed in 1877 (level 4), 
more than 100 years ago. Here, and throughout the se-
ries, levels of evidence are stated for referenced articles 
in accordance with the Oxford Centre for Evidence-
Based Medicine Levels of Evidence of May 2001 (see 
Table 1). However only 50%–70% of cholangitis pa-
tients present clinically with Charcot’s triad.2–8 In addi-
tion, Murphy’s sign9  (level 5) is useful (sensitivity of 
50%–70% and speciﬁ  city of 79%–96%) in diagnosing 
cholecystitis, and this sign is widely used in every coun-
try. Moreover, as many of the symptoms and concepts 
of these diseases referred to in textbooks and reference 
books vary from those originally stated, the issue of 
worldwide criteria is problematic. In view of these un-
favorable situations, we considered it necessary to clar-
ify the deﬁ  nitions, concepts of disease, and treatment 
methods for acute cholangitis and acute cholecystitis 
and establish universal criteria that can be widely rec-
ognized and used.
A working group to establish practical Guidelines for 
the Management of Cholangitis and Cholecystitis was 
organized in 2003 (chief researcher, Tadahiro Takada). 
This project was funded by a grant from the Japanese 
Ministry of Health, Labour, and Welfare, and was sup-
ported by the Japanese Society for Abdominal Emer-
gency Medicine, the Japan Biliary Association, and the 
Japanese Society of Hepato-Biliary-Pancreatic Surgery. 
The working group consisted of physicians engaged in 
gastroenterology, internal medicine, surgery, emer gency 
medicine, intensive care, and clinical epidemiology as 
the main members, and they started the work to prepare 
the Guidelines.
As the research progressed, the group was faced with 
the serious problem that high-level evidence regarding 
the treatment of acute biliary infection is poor. There-
fore, an exective committee meeting was convened, and 
the committee came to the following decision: the 
Guidelines would be evidence-based in general, but 
areas without evidence or with poor evidence (such as 
diagnosis and severity assessment) should be completed 
by obtaining high-level consensus among experts 
worldwide.
We established a publication committee and held 12 
meetings to prepare draft Guidelines in English (ver-
sion 3). Then we had several discussions on these draft 
Guidelines with leading experts in the ﬁ  eld throughout 
the world, via e-mail, leading to version 4. Finally, 
an International Consensus Meeting took place in 
Tokyo, on 1–2 April, 2006, to obtain international 
agreement on diagnostic criteria, severity assessment, 
and management.
We now publish the “Tokyo Guidelines for the 
Management of Cholangitis and cholecystitis”. These 
Guidelines consist of 13 articles, including “Discussion” 
sections containing comments of attendees at the con-
sensus conference and analyses of audience voting at 
the meeting.
We hope that these Guidelines will help their users 
to give optimal treatment according to their own spe-
cialty and capability, and thus provide their patients 
with the best medical treatment.
Background of Tokyo Guidelines
Biliary infections (acute cholangitis and cholecystitis) 
require appropriate management in the acute phase. 
Serious acute cholangitis may be lethal unless it is ap-
propriately managed in the acute phase. On the other 
hand, although various diagnostic and treatment meth-
odologies have been developed in recent years, they 
have not been assessed objectively and none of them 
has been established as a standard method for the man-
agement of these diseases. We carried out an extensive 
review of the English-language literature and found 
that there was little high-level evidence in this ﬁ  eld, and 
no systematically described practical manual for the 
ﬁ  eld. Most importantly, there are no standardized diag-
nostic criteria and severity assessments for acute cholan-
gitis and cholecystitis, therefore, we would like to 
establish standards for these items. The Tokyo Guide-
lines include evidence-based medicine and reﬂ  ect the 
international consensus obtained through earnest dis-
cussions among professionals in the ﬁ  eld on 1–2 April, 
2006, at the Keio Plaza Hotel, Tokyo, Japan. Concern-
ing the deﬁ  nitions in the practice guidelines, we have 
applied to the Japanese Institute of Medicine: Commit-
tee to Advise the Public Health Service on Clinical 
Practice Guidelines, to approve the systematically de-
veloped Guidelines to assist practioner and patient de-
cisions about appropriate healthcare for speciﬁ  c clinical 
circumstances.
Notes on the use of the Guidelines
The Guidelines are evidence-based, with the grade of 
recommendation also based on the evidence. The 
Guidelines also present the diagnostic criteria for and 
severity assessment of acute biliary infection. As the 
Guidelines address so many different subjects, indices 
are included at the end for the convenience of 
readers.
The practice Guidelines promulgated in this work do 
not represent a standard of practice. They are suggested 
plans of care, based on best available evidence and the 
consensus of experts, but they do not exclude other ap-
proaches as being within the standard of practice. For 
example, they should not be used to compel adherence 
to a given method of medical management, which meth-T. Takada et al.: Background of Tokyo Guidelines  3
od should be ﬁ  nally determined after taking account 
of the conditions at the relevant medical institution 
(staff levels, experience, equipment, etc.) and the char-
acteristics of the individual patient. However, responsi-
bility for the results of treatment rests with those who 
are directly engaged therein, and not with the consensus 
group. The doses of medicines described in the text of 
the Guidelines are for adult patients.
Methods of formulating the guidelines
With evidence-based medicine (EBM) as a core con-
cept, the Guidelines were prepared by the Research 
Group on the Preparation and Diffusion of Guidelines 
for the Management of Acute Cholangitis and Acute 
Cholecystitis (chief researcher, Tadahiro Takada), un-
der the auspices of the Japanese Ministry of Health, La-
bour, and Welfare, and the Working Group for Guideline 
Preparation, whose members were selected from ex-
perts in abdominal emergency medicine and epidemiol-
ogy by the Japanese Society for Abdominal Emergency 
Medicine, the Japan Biliary Association, and the Japa-
nese Society of Hepato-Biliary-Pancreatic Surgery.
In principle, the preparation of the Guidelines pro-
gressed with the systematic search, collection, and as-
sessment of references for the objective extraction of 
evidence. Next, the External Assessment Committee 
examined the Guidelines. Then we posted the draft 
guidelines on our website and had four open symposia, 
bginning in September 2004, to gain feedback for fur-
ther review. Subsequently, a Publication Committee 
was set up, and this committee had 12 meetings to pre-
pare draft Guidelines.
Re-examination of the draft Guidelines was then per-
formed, via e-mail, with experts on cholangitis and 
cholecystitis throughout the world. After ﬁ  nal agree-
ment was reached at the International Consensus Meet-
ing, held in Tokyo in April 2006, “the Tokyo Guidelines 
for the Management of Acute Cholangitis and Chole-
cystitis” were completed.
The process of extending the literature search
The literature was selected as follows: Using “cholangi-
tis” and “cholecystitis” as the medical subject heading 
(MeSH; explode) or the key search words, approxim-
ately 17  200 items were selected from Medline (Ovid; 
1966 to June 2003). These articles were subjected to a 
further screening with “human” as the “limiting word”. 
This screening provided 9618 items in English and in 
Japanese. A further 7093 literature publications were 
obtained from the Japana Centra Revuo Medicina 
(inter  net version), using “cholangitis”, “cholecystitis”, 
and “biliary infection” as the key words, with further 
screening with “human” as the “limiting word”. This 
process provided 6141 items. After the titles and ab-
stracts of a total of 15 759 works were examined by two 
committee members, 2494 were selected for a careful 
examination of their full texts.
Other literature quoted in these selected works, to-
gether with works suggested by the specialist committee 
members, were included in the examination.
To evaluate each article, a STARD (standards for 
reporting of diagnostic accuracy) checklist (Table 1)12 
was considered important. The purpose of this checklist 
is to evaluate the format and study process, in order to 
improve the accuracy and completeness of the reporting 
of studies of diagnostic accuracy.
However, the STARD checklist is not suitable for 
classifying various categories (e.g., therapy, prevention, 
etiology, harm, prognosis, diagnosis, differential diag-
nosis, economic and decision analysis) and levels of evi-
dence. Therefore, in the Guidelines, the science-based 
classiﬁ  cation used by the Cochrane Library (Table 2) 
was adopted.
The evidence obtained from each item of reference 
was evaluated in accordance with the science-based 
classiﬁ  cation used by the Cochrane Library (Table 2), 
and the quality of evidence for each parameter associ-
ated with the diagnosis and treatment of acute biliary 
infection was determined. As stated above, the level of 
evidence presented by each article was determined in 
accordance with the Oxford Centre for Evidence-Based 
Medicine Levels of Evidence (May 2001), prepared by 
Phillips et al.13 (Table 2). The terms used in the catego-
ries are explained in the footnote to Table 2.
Categories of evidence and grading of recommendations
Based on the results obtained from these procedures, 
grades of recommendation were determined, according 
to the system for ranking recommendations in clinical 
guidelines14–16 shown in Table 3, and mentioned, as re-
quired, in the text of the Guidelines. The grades of rec-
ommendation in the Guidelines are based on the Kish14 
method of classiﬁ  cation and others.15,16 Recommenda-
tions graded “A” (that is, “do it”) and “B” (that is, 
“probably do it”), are based on a high level of evidence, 
whereas those graded “D” (that is, “probably don’t do 
it”) or “E” (that is, “don’t do it”) reﬂ  ect a low level of 
evidence.
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Table 1.  STARD checklist for the reporting of studies of diagnostic accuracy
Section and       On page
topic Item  no.    no.
Title/Abstract/    1  Identify the article as a study of diagnostic accuracy (recommend MeSH heading
  Key words      “sensitivity and speciﬁ  city”)
Introduction    2  State the research questions or study aims, such as estimating diagnostic accuracy
      or comparing accuracy between tests or across participant groups
Methods   Describe
  Participants    3  The study population: the inclusion and exclusion criteria, setting and locations
      where the data were collected
    4  Participant recruitment: was recruitment based on presenting symptoms, results
      from previous tests, or the fact that the participants had received the index tests
      or the reference standard?
    5  Participant sampling: was the study population a consecutive series of participants
     deﬁ  ned by the selection criteria in items 3 and 4? If not, specify how participants 
      were further selected
    6  Data collection: was data collection planned before the index test and reference
      standard were performed (prospective study) or after (retrospective study)?
  Test methods    7  The reference standard and its rationale
    8 Technical  speciﬁ  cations of material and methods involved, including how and when
      measurements were taken, and/or cite references for index tests and reference 
      standard
   9 Deﬁ  nition of and rationale for the units, cutoffs, and/or categories of the results of
      the index tests and the reference standard
  10  The number, training, and expertise of the persons executing and reading the index
      tests and the reference standard
  11  Whether or not the readers of the index tests and reference standard were blind
      (masked) to the results of the other test, and describe any other clinical 
      information available to the readers
  Statistical   12  Methods for calculating or comparing measures of diagnostic accuracy, and the 
    methods      statistical methods used to quantify uncertainty (e.g., 95% conﬁ  dence intervals)
  13  Methods for calculating test reproducibility, if done
Results   Report
  Participants  14  When study was done, including beginning and ending dates of recruitment
  15  Clinical and demographic characteristics of the study population (e.g., age, sex
      spectrum of presenting symptoms, comorbidity, current treatments, recruitment 
      centers)
  16  The number of participants satisfying the criteria for inclusion that did or did not
      undergo the index tests and/or the reference standard; describe why participants 
      failed to receive either test (a ﬂ  ow diagram is strongly recommended)
  Test results  17  Time interval from the index tests to the reference standard, and any treatment
      administered between
  18  Distribution of severity of disease (deﬁ  ne criteria) in those with the target
      condition; other diagnoses in participants without the target condition
  19  A cross-tabulation of the results of the index tests (including indeterminate and
      missing results) by the results of the reference standard; for continuous results, 
      the distribution of the test results by the results of the reference standard
  20  Any adverse events from performing the index tests or the reference standard
  Estimates  21  Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., 95%
      conﬁ  dence intervals)
  22  How indeterminate results, missing responses, and outliers of the index tests 
      were handled
  23  Estimates of variability of diagnostic accuracy between subgroups of participants, 
      readers, or centers, if done
  24  Estimates of test reproducibility, if done
Discussion  25  Discuss the clinical applicability of the study ﬁ  ndings
Adapted from reference 12
MeSH, medical subject heading; STARD, standards for reporting of diagnostic accuracyT. Takada et al.: Background of Tokyo Guidelines  5
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f
 
c
o
h
o
r
t
 
s
t
u
d
i
e
s
 
e
i
t
h
e
r
 
r
e
t
r
o
s
p
e
c
t
i
v
e
 
c
o
h
o
r
t
 
>
2
 
d
i
a
g
n
o
s
t
i
c
 
s
t
u
d
i
e
s
 
o
f
 
2
b
 
a
n
d
 
b
e
t
t
e
r
 
s
t
u
d
i
e
s
 
>
2
 
e
c
o
n
o
m
i
c
 
s
t
u
d
i
e
s
 
 
s
t
u
d
i
e
s
 
o
r
 
u
n
t
r
e
a
t
e
d
 
 
 
c
o
n
t
r
o
l
 
g
r
o
u
p
s
 
i
n
 
R
C
T
s
2
b
 
I
n
d
i
v
i
d
u
a
l
 
c
o
h
o
r
t
 
s
t
u
d
y
 
R
e
t
r
o
s
p
e
c
t
i
v
e
 
c
o
h
o
r
t
 
s
t
u
d
y
 
 
E
x
p
l
o
r
a
t
o
r
y
d
 
c
o
h
o
r
t
 
s
t
u
d
y
 
w
i
t
h
 
R
e
t
r
o
s
p
e
c
t
i
v
e
 
c
o
h
o
r
t
 
s
t
u
d
y
,
 
A
n
a
l
y
s
i
s
 
b
a
s
e
d
 
o
n
 
c
l
i
n
i
c
a
l
l
y
 
(
i
n
c
l
u
d
i
n
g
 
l
o
w
-
q
u
a
l
i
t
y
 
R
C
T
;
 
o
r
 
f
o
l
l
o
w
-
u
p
 
o
f
 
u
n
t
r
e
a
t
e
d
 
 
g
o
o
d
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
s
;
 
o
r
 
p
o
o
r
 
f
o
l
l
o
w
-
u
p
 
s
e
n
s
i
b
l
e
 
c
o
s
t
s
 
o
r
 
a
l
t
e
r
n
a
t
i
v
e
s
;
 
 
e
.
g
.
,
 
<
8
0
%
 
f
o
l
l
o
w
-
u
p
)
 
c
o
n
t
r
o
l
 
p
a
t
i
e
n
t
s
 
i
n
 
a
n
 
R
C
T
;
 
 
C
D
R
b
 
a
f
t
e
r
 
d
e
r
i
v
a
t
i
o
n
,
 
o
r
 
 
l
i
m
i
t
e
d
 
r
e
v
i
e
w
(
s
)
 
o
f
 
t
h
e
 
 
D
e
r
i
v
a
t
i
o
n
 
o
f
 
C
D
R
b
 
o
r
 
 
v
a
l
i
d
a
t
e
d
 
o
n
l
y
 
o
n
 
s
p
l
i
t
-
s
a
m
p
l
e
j
 
 
e
v
i
d
e
n
c
e
,
 
o
r
 
s
i
n
g
l
e
 
s
t
u
d
i
e
s
;
 
a
n
d
 
 
v
a
l
i
d
a
t
e
d
 
o
n
 
s
p
l
i
t
-
s
a
m
p
l
e
j
 
o
r
 
d
a
t
a
b
a
s
e
s
 
 
i
n
c
l
u
d
i
n
g
 
m
u
l
t
i
-
w
a
y
 
s
e
n
s
i
t
i
v
i
t
y
 
 
 
o
n
l
y
 
 
 
a
n
a
l
y
s
e
s
2
c
 
“
O
u
t
c
o
m
e
s
”
 
r
e
s
e
a
r
c
h
;
 
“
O
u
t
c
o
m
e
s
”
 
r
e
s
e
a
r
c
h
 
 
E
c
o
l
o
g
i
c
a
l
 
s
t
u
d
i
e
s
 
A
u
d
i
t
 
o
r
 
o
u
t
c
o
m
e
s
 
r
e
s
e
a
r
c
h
 
e
c
o
l
o
g
i
c
a
l
 
s
t
u
d
i
e
s
3
a
 
S
R
 
(
w
i
t
h
 
h
o
m
o
g
e
n
e
i
t
y
a
)
 
 
 
S
R
 
(
w
i
t
h
 
h
o
m
o
g
e
n
e
i
t
y
a
)
 
o
f
 
3
b
 
S
R
 
(
w
i
t
h
 
h
o
m
o
g
e
n
e
i
t
y
a
)
 
S
R
 
(
w
i
t
h
 
h
o
m
o
g
e
n
e
i
t
y
a
)
 
o
f
 
3
b
 
o
f
 
c
a
s
e
-
c
o
n
t
r
o
l
 
s
t
u
d
i
e
s
 
 
a
n
d
 
b
e
t
t
e
r
 
s
t
u
d
i
e
s
 
o
f
 
3
b
 
a
n
d
 
b
e
t
t
e
r
 
s
t
u
d
i
e
s
 
a
n
d
 
b
e
t
t
e
r
 
s
t
u
d
i
e
s
3
b
 
I
n
d
i
v
i
d
u
a
l
 
c
a
s
e
-
c
o
n
t
r
o
l
 
 
N
o
n
-
c
o
n
s
e
c
u
t
i
v
e
 
s
t
u
d
y
;
 
o
r
 
N
o
n
-
c
o
n
s
e
c
u
t
i
v
e
 
c
o
h
o
r
t
 
A
n
a
l
y
s
i
s
 
b
a
s
e
d
 
o
n
 
l
i
m
i
t
e
d
 
s
t
u
d
y
 
 
w
i
t
h
o
u
t
 
c
o
n
s
i
s
t
e
n
t
l
y
 
a
p
p
l
i
e
d
 
s
t
u
d
y
,
 
o
r
 
v
e
r
y
 
l
i
m
i
t
e
d
 
a
l
t
e
r
n
a
t
i
v
e
s
 
o
r
 
c
o
s
t
s
,
 
p
o
o
r
-
q
u
a
l
i
t
y
 
 
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
s
 
p
o
p
u
l
a
t
i
o
n
 
e
s
t
i
m
a
t
e
s
 
o
f
 
d
a
t
a
,
 
b
u
t
 
i
n
c
l
u
d
i
n
g
 
 
 
 
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
e
s
 
i
n
c
o
r
p
o
r
a
t
i
n
g
 
 
 
 
 
 
c
l
i
n
i
c
a
l
l
y
 
s
e
n
s
i
b
l
e
 
v
a
r
i
a
t
i
o
n
s6  T. Takada et al.: Background of Tokyo Guidelines
T
a
b
l
e
 
2
.
 
C
o
n
t
i
n
u
e
d
 
 
 
 
D
i
f
f
e
r
e
n
t
i
a
l
 
T
h
e
r
a
p
y
/
p
r
e
v
e
n
t
i
o
n
,
 
 
 
d
i
a
g
n
o
s
i
s
/
s
y
m
p
t
o
m
 
E
c
o
n
o
m
i
c
 
a
n
d
L
e
v
e
l
 
a
e
t
i
o
l
o
g
y
/
h
a
r
m
 
P
r
o
g
n
o
s
i
s
 
D
i
a
g
n
o
s
i
s
 
p
r
e
v
a
l
e
n
c
e
 
s
t
u
d
y
 
d
e
c
i
s
i
o
n
 
a
n
a
l
y
s
e
s
 
4
 
C
a
s
e
-
s
e
r
i
e
s
 
(
a
n
d
 
p
o
o
r
-
q
u
a
l
i
t
y
 
C
a
s
e
-
s
e
r
i
e
s
 
(
a
n
d
 
 
C
a
s
e
-
c
o
n
t
r
o
l
 
s
t
u
d
y
,
 
p
o
o
r
 
o
r
 
C
a
s
e
-
s
e
r
i
e
s
 
o
r
 
s
u
p
e
r
s
e
d
e
d
 
A
n
a
l
y
s
i
s
 
w
i
t
h
 
n
o
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
a
l
y
s
i
s
 
c
o
h
o
r
t
 
a
n
d
 
c
a
s
e
-
c
o
n
t
r
o
l
 
p
o
o
r
-
q
u
a
l
i
t
y
 
p
r
o
g
n
o
s
t
i
c
 
n
o
n
-
i
n
d
e
p
e
n
d
e
n
t
 
r
e
f
e
r
e
n
c
e
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
s
 
s
t
u
d
i
e
s
k
)
 
c
o
h
o
r
t
 
s
t
u
d
i
e
s
l
)
 
s
t
a
n
d
a
r
d
5
 
E
x
p
e
r
t
 
o
p
i
\
n
i
o
n
 
w
i
t
h
o
u
t
 
E
x
p
e
r
t
 
o
p
i
n
i
o
n
 
w
i
t
h
o
u
t
 
E
x
p
e
r
t
 
o
p
i
n
i
o
n
 
w
i
t
h
o
u
t
 
e
x
p
l
i
c
i
t
 
E
x
p
e
r
t
 
o
p
i
n
i
o
n
 
w
i
t
h
o
u
t
 
E
x
p
e
r
t
 
o
p
i
n
i
o
n
 
w
i
t
h
o
u
t
 
e
x
p
l
i
c
i
t
 
e
x
p
l
i
c
i
t
 
c
r
i
t
i
c
a
l
 
a
p
p
r
a
i
s
a
l
,
 
o
r
 
e
x
p
l
i
c
i
t
 
c
r
i
t
i
c
a
l
 
a
p
p
r
a
i
s
a
l
,
 
c
r
i
t
i
c
a
l
 
a
p
p
r
a
i
s
a
l
,
 
o
r
 
b
a
s
e
d
 
o
n
 
e
x
p
l
i
c
i
t
 
c
r
i
t
i
c
a
l
 
a
p
p
r
a
i
s
a
l
,
 
o
r
 
c
r
i
t
i
c
a
l
 
a
p
p
r
a
i
s
a
l
,
 
o
r
 
b
a
s
e
d
 
o
n
 
b
a
s
e
d
 
o
n
 
p
h
y
s
i
o
l
o
g
y
,
 
b
e
n
c
h
 
o
r
 
b
a
s
e
d
 
o
n
 
p
h
y
s
i
o
l
o
g
y
,
 
p
h
y
s
i
o
l
o
g
y
,
 
b
e
n
c
h
 
r
e
s
e
a
r
c
h
,
 
o
r
 
b
a
s
e
d
 
o
n
 
p
h
y
s
i
o
l
o
g
y
,
 
b
e
n
c
h
 
e
c
o
n
o
m
i
c
 
t
h
e
o
r
y
 
o
r
 
“
ﬁ
 
r
s
t
 
p
r
i
n
c
i
p
l
e
s
”
 
r
e
s
e
a
r
c
h
,
 
o
r
 
“
ﬁ
 
r
s
t
 
p
r
i
n
c
i
p
l
e
s
”
 
b
e
n
c
h
 
r
e
s
e
a
r
c
h
,
 
“
ﬁ
 
r
s
t
 
p
r
i
n
c
i
p
l
e
s
”
 
r
e
s
e
a
r
c
h
,
 
o
r
 
“
ﬁ
 
r
s
t
 
p
r
i
n
c
i
p
l
e
s
”
 
 
o
r
 
“
ﬁ
 
r
s
t
 
p
r
i
n
c
i
p
l
e
s
”
U
s
e
r
s
 
c
a
n
 
a
d
d
 
a
 
m
i
n
u
s
-
s
i
g
n
 
“
−
”
 
t
o
 
d
e
n
o
t
e
 
t
h
e
 
l
e
v
e
l
 
t
h
a
t
 
f
a
i
l
s
 
t
o
 
p
r
o
v
i
d
e
 
a
 
c
o
n
c
l
u
s
i
v
e
 
a
n
s
w
e
r
 
b
e
c
a
u
s
e
 
o
f
:
 
E
I
T
H
E
R
 
a
 
s
i
n
g
l
e
 
r
e
s
u
l
t
 
w
i
t
h
 
a
 
w
i
d
e
 
c
o
n
ﬁ
 
d
e
n
c
e
 
i
n
t
e
r
v
a
l
 
(
s
u
c
h
 
t
h
a
t
,
 
f
o
r
 
e
x
a
m
p
l
e
,
 
a
n
 
A
R
R
 
i
n
 
a
n
 
R
C
T
 
i
s
 
n
o
t
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
b
u
t
 
w
h
o
s
e
 
c
o
n
ﬁ
 
d
e
n
c
e
 
i
n
t
e
r
v
a
l
s
 
f
a
i
l
 
t
o
 
e
x
c
l
u
d
e
 
c
l
i
n
i
c
a
l
l
y
 
i
m
p
o
r
t
a
n
t
 
b
e
n
e
ﬁ
 
t
 
o
r
 
h
a
r
m
)
 
(
N
o
t
e
 
#
1
)
,
 
O
R
 
a
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
w
i
t
h
 
t
r
o
u
b
l
e
s
o
m
e
 
(
a
n
d
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
ﬁ
 
c
a
n
t
)
 
h
e
t
e
r
o
g
e
n
e
i
t
y
 
(
N
o
t
e
 
#
2
)
.
 
S
u
c
h
 
e
v
i
d
e
n
c
e
 
i
s
 
i
n
c
o
n
c
l
u
s
i
v
e
,
 
a
n
d
 
t
h
e
r
e
f
o
r
e
 
c
a
n
 
o
n
l
y
 
g
e
n
e
r
a
t
e
 
g
r
a
d
e
 
D
 
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
 
(
N
o
t
e
 
#
3
)
S
R
,
 
S
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
;
 
R
C
T
,
 
R
a
n
d
o
m
i
z
e
d
 
c
o
n
t
r
o
l
l
e
d
 
t
r
i
a
l
;
 
A
R
R
,
 
a
b
s
o
l
u
t
e
 
r
i
s
k
 
r
e
d
u
c
t
i
o
n
a
 
B
y
 
h
o
m
o
g
e
n
e
i
t
y
,
 
w
e
 
m
e
a
n
 
a
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
t
h
a
t
 
i
s
 
f
r
e
e
 
o
f
 
w
o
r
r
i
s
o
m
e
 
v
a
r
i
a
t
i
o
n
s
 
(
h
e
t
e
r
o
g
e
n
e
i
t
y
)
 
i
n
 
t
h
e
 
d
i
r
e
c
t
i
o
n
s
 
a
n
d
 
d
e
g
r
e
e
s
 
o
f
 
r
e
s
u
l
t
s
 
b
e
t
w
e
e
n
 
i
n
d
i
v
i
d
u
a
l
 
s
t
u
d
i
e
s
.
 
N
o
t
 
a
l
l
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
s
 
w
i
t
h
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
ﬁ
 
c
a
n
t
 
h
e
t
e
r
o
g
e
n
e
i
t
y
 
n
e
e
d
 
b
e
 
w
o
r
r
i
s
o
m
e
,
 
a
n
d
 
n
o
t
 
a
l
l
 
w
o
r
r
i
s
o
m
e
 
h
e
t
e
r
o
g
e
n
e
i
t
y
 
n
e
e
d
 
b
e
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
ﬁ
 
c
a
n
t
.
 
A
s
 
n
o
t
e
d
 
a
b
o
v
e
,
 
s
t
u
d
i
e
s
 
d
i
s
p
l
a
y
i
n
g
 
w
o
r
r
i
s
o
m
e
 
h
e
t
e
r
o
g
e
n
e
i
t
y
 
s
h
o
u
l
d
 
b
e
 
t
a
g
g
e
d
 
w
i
t
h
 
a
 
“
−
”
 
a
t
 
t
h
e
 
e
n
d
 
o
f
 
t
h
e
i
r
 
d
e
s
i
g
n
a
t
e
d
 
l
e
v
e
l
b
 
C
l
i
n
i
c
a
l
 
d
e
c
i
s
i
o
n
 
r
u
l
e
.
 
T
h
e
s
e
 
a
r
e
 
a
l
g
o
r
i
t
h
m
s
 
o
r
 
s
c
o
r
i
n
g
 
s
y
s
t
e
m
s
 
w
h
i
c
h
 
l
e
a
d
 
t
o
 
a
 
p
r
o
g
n
o
s
t
i
c
 
e
s
t
i
m
a
t
i
o
n
 
o
r
 
a
 
d
i
a
g
n
o
s
t
i
c
 
c
a
t
e
g
o
r
y
c
 
S
e
e
 
n
o
t
e
 
#
2
 
f
o
r
 
a
d
v
i
c
e
 
o
n
 
h
o
w
 
t
o
 
u
n
d
e
r
s
t
a
n
d
,
 
r
a
t
e
,
 
a
n
d
 
u
s
e
 
t
r
i
a
l
s
 
o
r
 
o
t
h
e
r
 
s
t
u
d
i
e
s
 
w
i
t
h
 
w
i
d
e
 
c
o
n
ﬁ
 
d
e
n
c
e
 
i
n
t
e
r
v
a
l
s
d
 
V
a
l
i
d
a
t
i
n
g
 
s
t
u
d
i
e
s
 
t
e
s
t
 
t
h
e
 
q
u
a
l
i
t
y
 
o
f
 
a
 
s
p
e
c
i
ﬁ
 
c
 
d
i
a
g
n
o
s
t
i
c
 
t
e
s
t
,
 
b
a
s
e
d
 
o
n
 
p
r
i
o
r
 
e
v
i
d
e
n
c
e
.
 
A
n
 
e
x
p
l
o
r
a
t
o
r
y
 
s
t
u
d
y
 
c
o
l
l
e
c
t
s
 
i
n
f
o
r
m
a
t
i
o
n
 
a
n
d
 
t
r
a
w
l
s
 
t
h
e
 
d
a
t
a
 
(
e
.
g
.
,
 
u
s
i
n
g
 
a
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
i
s
)
 
t
o
 
ﬁ
 
n
d
 
w
h
i
c
h
 
f
a
c
t
o
r
s
 
a
r
e
 
“
s
i
g
n
i
ﬁ
 
c
a
n
t
”
e
 
G
o
o
d
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
s
 
a
r
e
 
i
n
d
e
p
e
n
d
e
n
t
 
o
f
 
t
h
e
 
t
e
s
t
,
 
a
n
d
 
a
r
e
 
a
p
p
l
i
e
d
 
b
l
i
n
d
l
y
 
o
r
 
o
b
j
e
c
t
i
v
e
l
y
 
t
o
 
a
l
l
 
p
a
t
i
e
n
t
s
.
 
P
o
o
r
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
s
 
a
r
e
 
h
a
p
h
a
z
a
r
d
l
y
 
a
p
p
l
i
e
d
,
 
b
u
t
 
s
t
i
l
l
 
i
n
d
e
p
e
n
d
e
n
t
 
o
f
 
t
h
e
 
t
e
s
t
.
 
U
s
e
 
o
f
 
a
 
n
o
n
i
n
d
e
p
e
n
d
e
n
t
 
r
e
f
e
r
e
n
c
e
 
s
t
a
n
d
a
r
d
 
(
w
h
e
r
e
 
t
h
e
 
“
t
e
s
t
”
 
i
s
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
“
r
e
f
e
r
e
n
c
e
”
,
 
o
r
 
w
h
e
r
e
 
t
h
e
 
“
t
e
s
t
i
n
g
”
 
a
f
f
e
c
t
s
 
t
h
e
 
“
r
e
f
e
r
e
n
c
e
”
)
 
i
m
p
l
i
e
s
 
a
 
l
e
v
e
l
 
4
 
s
t
u
d
y
f
 
G
o
o
d
 
f
o
l
l
o
w
-
u
p
 
i
n
 
a
 
d
i
f
f
e
r
e
n
t
i
a
l
 
d
i
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Diffusion of Guidelines for the Management of Acute 
Cholangitis (H-15-Medicine-30), with a research sub sidy 
for ﬁ  scal 2003 and 2004 (Integrated Research Project 
for Assessing Medical Technology) sponsored by the 
Japanese Ministry of Health, Labour, and Welfare.
We also truly appreciate the panelists who cooper-
ated with and contributed signiﬁ  cantly to the Interna-
tional Consensus Meeting held in Tokyo on April 1 and 
2, 2006.
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Discussion at the Tokyo International 
Consensus Meeting
Tadahiro Takada (Japan): “Dr. Strasberg, please ex-
plain the difference between a ‘Guidelines’ and ‘Stand-
ards’ in your mind?”
Steven Strasberg (USA): “To me, ‘guidelines’ repre-
sent a suggested course of action based on available 
evidence. They do not imply that other courses of action 
are below an acceptable level of care. Practice ‘stand-
ards’ are different, in that they imply that actions other 
than those listed as acceptable practice standards are 
below the level of acceptable care. It is particularly true 
that, in an area in which high levels of evidence are not 
available, that guidelines are not construed to be stand-
ards. Reliance on expert opinion to form guidelines may 
be useful, but even a consensus of experts may not be 
correct. For this reason a statement of the following 
type should be inserted in the introduction. ‘The prac-
tice guidelines promulgated in this work do not repre-
sent a standard of practice. They are a suggested plan 
of care based on best available evidence and a consen-
sus of experts, but they do not exclude other approaches 
as being within the standard of practice’.”
Table 3.  Grading system for ranking recommendations in clinical guidelines14–16
Grade of recommendation
A  Good evidence to support a recommendation for use
B  Moderate evidence to support a recommendation for use
C  Poor evidence to support a recommendation, or the effect may not exceed the adverse effects 
and/or inconvenience (toxicity, interaction between drugs and cost)
D  Moderate evidence to support a recommendation against use
E  Good evidence to support a recommendation against use8  T. Takada et al.: Background of Tokyo Guidelines
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